| UNIVERSITAT DE LES ILLES BALEARS Patent applications |
| Patent application number | Title | Published |
|---|
| 20100267630 | USE OF LEPTIN IN THE PREVENTION OF UNHEALTHY FOOD HABITS AND CARDIOVASCULAR DISEASES - The present invention is addressed to the use of leptin, a fragment of leptin or a mimetic product of leptin action, in the preparation of a pharmaceutical composition, a food composition and/or a nutritional supplement for the prevention of unhealthy food habits and/or cardiovascular disorders during adulthood. | 10-21-2010 |
| 20100141804 | Image data processing method by reducing image noise, and camera integrating means for implementing said method - The invention concerns image data processing, through noise reduction comprising the following steps: associating a learning zone (ZA) with a reference point (Pref) of the image (IM); for each variable point (PC, PC′,) of the learning zone, evaluating a distance (d, d′,) between: values of points in a first window (f | 06-10-2010 |
| 20090203650 | USE OF PHYTATE AS AGENT INHIBITING DISSOLUTION OF CRYSTALS OF CALCIUM SALTS FOR THE PREVENTION OF OSTEOPOROSIS - The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts. | 08-13-2009 |
| 20090035232 | FIXED-DOSE ASSOCIATION OF PHYTATE AND ZINC - The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallisation of hydroxyapatite in humans. | 02-05-2009 |
